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NetherlandsIntroduction: CKD273 is a urinary biomarker, which in advanced chronic kidney disease predicts further
deterioration. We investigated whether CKD273 can also predict a decline of estimated glomerular filtra-
tion rate (eGFR) to <60 ml/min per 1.73 m2.
Methods: In analyses of 2087 individuals from 6 cohorts (46.4% women; 73.5% with diabetes; mean
age, 46.1 years; eGFR $ 60 ml/min per 1.73 m2, 100%; urinary albumin excretion rate [UAE] $20
mg/min, 6.2%), we accounted for cohort, sex, age, mean arterial pressure, diabetes, and eGFR at
baseline and expressed associations per 1-SD increment in urinary biomarkers.
Results: Over 5 (median) follow-up visits, eGFR decreased more with higher baseline CKD273 than
UAE (1.64 vs. 0.82 ml/min per 1.73 m2; P < 0.0001). Over 4.6 years (median), 390 participants experienced a
first renal endpoint (eGFR decrease by $10 to <60 ml/min per 1.73 m2), and 172 experienced an endpoint
sustained over follow-up. The risk of a first and sustained renal endpoint increased with UAE (hazard
ratio $ 1.23; P # 0.043) and CKD273 ($ 1.20; P # 0.031). UAE ($20 mg/min) and CKD273 ($0.154)
thresholds yielded sensitivities of 30% and 33% and specificities of 82% and 83% (P# 0.0001 for difference
between UAE and CKD273 in proportion of correctly classified individuals). As continuous markers,
CKD273 (P ¼ 0.039), but not UAE (P ¼ 0.065), increased the integrated discrimination improvement, while
both UAE and CKD273 improved the net reclassification index (P # 0.0003), except for UAE per threshold
(P ¼ 0.086).
Discussion: In conclusion, while accounting for baseline eGFR, albuminuria, and covariables, CKD273
adds to the prediction of stage 3 chronic kidney disease, at which point intervention remains an achievable
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C hronic kidney disease (CKD), defined as abnor-malities of kidney structure or function lasting for
more than 3 months,1 is a major health problem
affecting 10% of the general population and thereby
decreases the quality of life of millions of people.2–4
Compared with other chronic age-related illnesses,
relatively few clinical trials have addressed the pre-
vention of progression in patients with CKD.5 One of
the underlying reasons is the long follow-up required
to reach severe endpoints, such as doubling of serum
creatinine6 or a 50% decrease in the estimated
glomerular filtration rate (eGFR),7 the need for renal
replacement therapy,6,7 or death.6 In 2016, the Euro-
pean Medicines Agency (EMA) proposed that primary
efficacy endpoints in trials with renal outcomes can be
the prevention or delay of renal function decline
defined as time to or the incidence rate of stage 3 CKD
with or without albuminuria or proteinuria.8 A recent
meta-analysis of 1.7 million subjects demonstrated that
a 30% reduction in eGFR over 2 years predicted end-
stage renal disease and death9 and thereby supported
the concept of using shorter-term endpoints as pro-
posed by the EMA.
Capillary electrophoresis coupled with high-
resolution mass spectrometry (CE-MS) enables
detection of more than 5000 peptide fragments in
urine samples.10–12 CKD273 is a multidimensional
urinary biomarker consisting of 273 peptide frag-
ments,10,13 which in patients with advanced CKD
predicts further deterioration of renal function.14,15
The Food and Drug Administration recently
encouraged further studies of CKD273 as a tool for
the diagnosis and risk prediction in CKD.13 In
keeping with the EMA recommendation8 and the
Food and Drug Administration statement,13 the
objective of the present study was to investigate
whether CKD273 also predicts the incidence of eGFR
to less than 60 ml/min per 1.73 m2, at which point
intervention16 is still an option before structural al-
terations associated with later stages of CKD render
stopping or reversing the disease processes difficult,
if not impossible.
METHODS
Participants
The Human Urine Proteome Database available at
Mosaiques Diagnostics (Hannover, Germany)17 in-
cludes anonymized clinical information on participantsInternational Reports (2017) 2, 1066–1075enrolled in several studies, as well as urinary proteomic
signatures, including CKD273. These studies comply
with the Declaration of Helsinki18 and received ethical
approval from the pertinent institutional review
boards. All participants gave informed written consent.
The Ethics Committee of the University of Glasgow
authorized the current analysis (approval number 3115-
2016). To be eligible for analysis, the following criteria
had to be fulfilled: (i) eGFR at baseline of 60 ml/min per
1.73 m2 or higher; (ii) repeat assessment of eGFR during
a follow-up of at least 2 years; and (iii) information
available on clinically relevant covariables, including
sex, age, systolic and diastolic blood pressure, serum
creatinine, and albuminuria.
The number of participants in the Human Urine
Proteome Database complying with the aforementioned
eligibility criteria totaled 2087. Participants were: (i)
patients enrolled in the Diabetes Retinopathy Cande-
sartan Trialswith type 1 (DIRECT1; n¼ 740)19 and type 2
(DIRECT2; n ¼ 618)20 diabetes; (ii) patients with type 2
diabetes recruited into a Dutch study (PREvention
of DIabetic ComplicaTIONS [PREDICTIONS])21 aimed
at identifying disease pathway–specific biomarkers
(n ¼ 96), (iii) and patients with diabetes recruited from
clinics in Australia (n ¼ 47)22 and Hannover, Germany
(n¼ 22).16 The remaining 564 analyzed individuals were
enrolled in the Flemish Study on Environment, Genes
and Health Outcomes (FLEMENGHO).23Assessment of Renal Function
Estimated GFR was calculated from serum creatinine by
the Chronic Kidney Disease Epidemiology Collaboration
equation.24 The primary renal endpoint was a decrease
in eGFR from baseline to follow-up by at least 10
ml/min per 1.73 m2 to less than 60 ml/min per 1.73 m2.
A sustained renal endpoint required that the impair-
ment of glomerular function be maintained for at least 3
months with no increase above 60 ml/min per 1.73 m2
at any time during further follow-up. Estimated GFR
categories, defined according to the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
guidelines,25 were eGFR $90, 89–60, 59–45, 44–30,
29–15, and <15 ml/min per 1.73 m2 for stages 1, 2, 3A,
3B, 4, and 5, respectively. In keeping with the sug-
gestion to use declines in eGFR smaller than those
associated with a doubling of serum creatinine,9 in a
sensitivity analysis, we redefined the renal endpoint as
a decrease in eGFR by 30% or more over 2 years.1067
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expressed urinary albumin excretion rate (UAE) in mi-
crograms per minute. This involved a conversion from
milligrams per 24 hours in the Flemish Study on Envi-
ronment, Genes and Health Outcomes (FLEMENGHO)23
and a conversion from milligrams per liter in the
PREvention of DIabetic ComplicaTIONS (PREDICTIONS)
(n ¼ 96) and in the Australian22 (n ¼ 47) and German16
(n ¼ 22) patients, assuming a diuresis of 1500 ml/day.
The cutoff threshold for UAE was 20 mg/min, approxi-
mately corresponding to a 24-hour albuminuria of
30 mg.26
Measurement of CKD273
Detailed information about urine sample preparation,
proteome analysis by capillary-electrophoresis online
coupled to electrospray micro time-of-flight mass spec-
trometry, data processing, and sequencing is available
in previous publications.27,28 CKD273, measured at
baseline, is a multidimensional classifier based on 273
urinary peptides derived by support vector machine
modeling.10,13 For normalization of analytical and urine
dilution variances, the mass spectrometric signals were
normalized by using 29 internal standard peptides
present in at least 90% of all urine samples with small
SDs.29 In previous studies,11,30 investigators proposed
cutoff thresholds for CKD273 of 0.154 and 0.343 to
predict early and advanced CKD.
Statistical Analyses
For database management and statistical analysis, we
used the SAS system, version 9.4 (SAS Institute Inc.,
Cary, NC). Means were compared by using the large-
sample z-test, and proportions, by the Fisher exact
test. We rank normalized the distributions of albu-
minuria by sorting measurements from the smallest to
the highest and then applying the inverse cumulative
normal function.31
Changes in eGFR during follow-up, as predicted by
baseline UAE and CKD273, were assessed from mixed
models adjusted for sex, age, mean arterial pressure
(i.e., diastolic blood pressure plus one-third of the
difference between systolic and diastolic blood pres-
sure), and history of diabetes mellitus (categorical
variable coded 0 or 1). These mixed models accounted
for the varying numbers of follow-up eGFR measure-
ments and clustering of the observations within in-
dividuals and study centers. In exploratory analyses,
we assessed the cumulative incidence of the primary
(first) renal endpoint by quartiles of the distributions of
UAE and CKD273, while stratifying for center and
adjusting for baseline eGFR, sex, age, mean arterial
pressure, and history of diabetes mellitus. Next, we
used similarly adjusted proportional hazard regression1068to model time to the first and sustained renal endpoints.
For the calculation of relative risk in the sensitivity
analysis, we applied logistic regression.
We assessed the added value of UAE and CKD273 to
predict study endpoints from nested Cox models and
the log likelihood ratio test and from the integrated
discrimination improvement (IDI) and the net reclassi-
fication improvement (NRI).32 IDI is the difference
between the discrimination slopes of the basic model
and the basic model extended with the biomarker. The
discrimination slope is the difference in predicted
probabilities (%) between subjects with and without
endpoint. To calculate NRI, we predicted in each
participant the 5-year risk of a renal event from a Cox
model with and without the biomarker.32 If P(up/event) is
the percentage of subjects with events whose predicted
probability is increased by adding the biomarker to the
model and if P(up/nonevent) is the percentage of subjects
without events whose predicted probability is
increased, then NRI ¼ 2  (P[up/event] – P[up/nonevent]).
Finally, we assessed the performance of published
thresholds of UAE26 and CKD27311,30 from 2--2 tables
and applied the McNemar test for the pairwise com-
parison of proportions. Running a published SAS
macro33 over our current data, we determined thresh-
olds for UAE and CKD273, yielding a specificity of
90%, and we compared the sensitivity of the so
derived UAE and CKD273 thresholds.
RESULTS
Baseline Characteristics of Participants
The entire study group (n ¼ 2087) included 968 women
(46.4%), 1533 (73.5%) patients with diabetes mellitus,
and 388 (18.6%) patients with hypertension. At base-
line, 1959 participants (93.9%) and 1824 (87.4%) did not
exceed the thresholds for albuminuria (UAE $20
mg/min) or a CKD273 signal indicative of CKD ($0.154),
respectively.Mean values in the entire study population
were 46.1 15.2 years for age; 125.9 14.7 mm Hg and
76.9  8.2 mm Hg for systolic and diastolic blood
pressure, respectively; 87.5  12.4 mmol/l for serum
creatinine; and 81.0 13.0 ml/min per 1.73 m2 for eGFR.
Progressors experienced a decrease in eGFR during
follow-up of at least 10 ml/min per 1.73m2 to less than 60
ml/min per 1.73 m2. Progressors compared with non-
progressors (Table 1) were older (P< 0.0001), had higher
systolic and mean arterial blood pressure (P < 0.0001),
higher UAE (P < 0.0001), and stronger CKD273 signal
intensity (P< 0.0001) but had lower eGFR (P< 0.0001).
Change in eGFR
The median number of eGFR data points was 6 (inter-
quartile range, 5–6) in progressors and 5 (interquartile
range, 2–6) in nonprogressors. From baseline to lastKidney International Reports (2017) 2, 1066–1075
Table 1. Baseline characteristics of participants by renal function
Characteristic Progressors Nonprogressors
Number of participants (%)
All participants in category 390 1697
Women 236 (60.5)a 732 (43.1)
Diabetes mellitus 358 (91.8)a 1175 (69.2)
Hypertension 110 (28.2)a 278 (16.4)
UAE $20 mg/min 40 (10.3)b 89 (5.2)
CDK273 signal $0.154 and <0.343 34 (8.7)c 99 (5.8)
CKD273 signal $0.343 54 (13.8)a 76 (4.5)
Mean of characteristic
Age (yr) 55.2  11.7a 44.0  15.0
Systolic pressure (mm Hg) 131.4  14.8a 124.7  14.4
Diastolic pressure (mm Hg) 77.3  7.5 76.8  8.3
Mean arterial pressure (mm Hg) 95.4  8.8a 92.7  9.2
Serum creatinine (mmol/L) 87.5  12.4 88.4  12.4
eGFR (ml/min per 1.73 m2) 73.0  9.93a 82.8  12.9
UAE (mg/min)c 6.76 (3.50 to 9.51)a 5.24 (3.12 to 7.08)
CKD273 –0.17  0.43a –0.40  0.41
Follow-up (yr) 4.73 (4.22–4.94)a 4.50 (4.16–5.11)
eGFR data points 6 (5–6)a 5 (2–6)
Averages are arithmetic means  SD or geometric means (interquartile range). Esti-
mated glomerular filtration rate was derived from serum creatinine by the Chronic
Kidney Disease Epidemiology Collaboration formula.
CKD273, urinary proteomic biomarker; eGFR, estimated glomerular filtration rate; UAE,
urinary albumin excretion rate.
Progressors had an eGFR decrease by at least 10 ml/min per 1.73 m2 to less than 60 ml/
min per 1.73 m2. P values indicate significance of the difference between progressors
and nonprogressors.
aP # 0.0001.
bP # 0.001.
cP # 0.05.
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ml/min per 1.73 m2 (95% confidence interval [CI], 3.62–
4.29) in progressors and 1.27 ml/min per 1.73 m2 (95%
CI, 1.07–1.49) in nonprogressors. In repeated-measures
analyses of all participants covering the entire follow-
up, we stratified for center and adjusted estimates for
baseline eGFR, sex, age, mean arterial pressure, history
of diabetes mellitus, and follow-up duration; and we
expressed effect sizes per 1-SD increments in the
urinary biomarkers. In models including a single
marker, eGFR decreased by 1.20 ml/min per 1.73 m2
(95% CI, 1.00–1.40; P < 0.0001) in relation to UAE and
by 1.84 ml/min per 1.73 m2 (CI, 1.64–2.04; P < 0.0001)
in relation to CKD273. In models including both bio-
markers, the decline in eGFR averaged 1.64 ml/min per
1.73 m2 (95% CI, 1.43–1.84; P < 0.0001) for CKD273
and 0.82 ml/min per 1.73 m2 (95% CI, 0.62–1.02;
P < 0.0001) for UAE (P for difference between the 2
markers <0.0001).
Baseline UAE and CKD273 as Continuous
Predictors
Over a median follow-up of 4.6 years (interquartile
range, 4.1–5.1; 5th to 95th percentile interval, 2.1 to 5.7),
the 2087 participants experienced 390 primary renal
endpoints at a rate of 43.2 per 1000 person-years (95%
CI, 41.1–43.3). After the 564 participants with only aKidney International Reports (2017) 2, 1066–1075single follow-up eGFR assessment were excluded, 172
sustained renal endpoints occurred at a rate of 26.5
(95% CI, 26.4–26.6) per 1000 person-years. Among 390
patients with a primary renal endpoint, at the end of
follow-up, 340 had progressed to stage 3A, 44 to stage
3B, 4 to stage 4, and 2 to stage 5.Whenwe had accounted
for center, sex, age, mean arterial pressure, the presence
of diabetes mellitus, and baseline eGFR, the cumulative
incidence of the first (primary) endpoint did not show a
coherent gradient across quartiles of the UAE distribu-
tion, with the incidence for the low-medium quartile
running above that of the medium-high group. In
contrast, the cumulative incidence of a first renal
endpoint consistently increased from the lowest to
highest quartile of CKD273 (Figure 1).
Next, we modeled the risk associated with eGFR,
UAE, and CKD273 analyzed as continuous variables.
We expressed the risk per 1-SD increments in the
biomarkers (Table 2). All models accounted for study
center, sex, age, mean arterial pressure, and the pres-
ence of diabetes mellitus. If we introduced eGFR, UAE,
and CKD273 as single predictors in the multivariable-
adjusted models, the hazard ratios for the first renal
endpoint were 0.71 (P < 0.0001) for eGFR, 1.29
(P ¼ 0.0002) for UAE, and 1.29 (P < 0.0001) for
CKD273; the corresponding point estimates for a sus-
tained renal endpoint were 0.38 (P < 0.0001), 1.19
(P ¼ 0.096), and 1.18 (P ¼ 0.050), respectively. In
models additionally accounting for baseline eGFR, the
hazard ratios for a first renal endpoint associated with
UAE and CKD273 were 1.31 (P < 0.0001) and 1.30
(P < 0.0001), and for a sustained renal endpoint, 1.25
(P ¼ 0.027) and 1.21 (P ¼ 0.020), respectively. The c2
statistics of the log likelihood ratios (Table 3)
confirmed that CKD273 improved the model fit over
and beyond baseline eGFR for the first (P < 0.0001)
and sustained (P # 0.049) renal endpoints, whereas
UAE did so for the first renal endpoint (P # 0.0002)
but required the presence in the model of baseline
eGFR to reach significance for the sustained renal
endpoint (P ¼ 0.027). Similarly, in models that already
included baseline eGFR and UAE (Tables 2 and 3),
introduction of CKD273 improved the model fit (P #
0.030), yielding hazard ratios of 1.28 (P < 0.0001) and
1.20 (P ¼ 0.031) for the first and sustained renal out-
comes, respectively. Figure 2 shows the 5-year absolute
risk of the renal endpoints in relation to UAE
(Figure 2a and 2c) at different levels of CKD273 and
vice versa. It illustrates that in fully adjusted models,
both UAE and CKD273 predicted first and sustained
renal outcomes (P # 0.028). As continuous variables
(Table 4), CKD273 (P ¼ 0.039), but not UAE (P ¼
0.065), improved the IDI, while both markers increased
the NRI (P # 0.0003).1069
Figure 1. Cumulative incidence of a first renal endpoint by quartiles of the distributions of urinary albumin excretion rate (UAE) (a) and CKD273
(b). Midpoints of the quartiles (Q1, Q2, Q3, and Q4) were 2.0, 3.5, 6.0, and 13.0 mg/min for UAE and -0.81, -0.52, -0.25, and 0.16 for CKD273.
Incidence rates were adjusted for center, sex, age, mean arterial pressure, presence of diabetes mellitus, and baseline estimated glomerular
filtration rate. The cumulative incidence of the first (primary) endpoint did not show a consistent gradient across quartiles of the UAE distri-
bution, whereas the cumulative incidence of a first renal endpoint consistently increased from the lowest to highest quartile of CKD273. For
UAE, the Q2 line runs above the Q3 line, whereas for CKD273, the 4 lines run according to the order of the quartiles.
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Predictors
In the next step of our analysis, we evaluated
established thresholds of UAE26 and CKD27311,30 as
predictors of CKD progression. In all participants
(Table 5), the UAE cutoff value of 20 mg/min and the
CKD273 thresholds of 0.154 and 0.343 yielded
sensitivities of 30%, 33%, and 42% and specificities
of 82%, 83%, and 83%, respectively. TheTable 2. Multivariable-adjusted hazard ratios predicting progression
of chronic kidney disease
Models
First renal endpoint
(390 vs. 1697)
Sustained renal endpoint
(172 vs. 1351)
Hazard ratio P value Hazard ratio P value
Single-biomarkermodels
Baseline eGFR 0.71 (0.61 to 0.84) <0.0001 0.38 (0.29 to 0.52) <0.0001
UAE 1.29 (1.13 to 1.47) 0.0002 1.19 (0.97 to 1.45) 0.096
CKD273 1.29 (1.15 to 1.44) <0.0001 1.18 (1.00 to 1.40) 0.050
Two-biomarker models
Baseline eGFR 0.70 (0.60 to 0.83) <0.0001 0.37 (0.27 to 0.50) <0.0001
UAE 1.31 (1.14 to 1.50) <0.0001 1.25 (1.03 to 1.53) 0.027
Baseline eGFR 0.71 (0.61 to 0.83) <0.0001 0.38 (0.28 to 0.51) <0.0001
CKD273 1.30 (1.16 to 1.45) <0.0001 1.21 (1.03 to 1.43) 0.020
Three-biomarker model
Baseline eGFR 0.50 (0.60 to 0.82) <0.0001 0.37 (0.27 to 0.50) <0.0001
UAE 1.27 (1.11 to 1.46) 0.0004 1.23 (1.01 to 1.51) 0.043
CKD273 1.28 (1.14 to 1.43) <0.0001 1.20 (1.02 to 1.42) 0.031
CKD273, urinary proteomic biomarker; eGFR, estimated glomerular filtration rate derived
from serum creatinine by the Chronic Kidney Disease Epidemiology Collaboration for-
mula; UAE, urinary albumin excretion rate. Hazard ratios express the increase in risk
associated with a 1-SD increase in the baseline biomarkers: 13.1 ml/min per 1.73 m2 for
estimated glomerular filtration rate, 1.00 for urinary albumin excretion rate, and 0.41 for
CKD273. Associations were stratified by center and accounted for sex, age, mean
arterial pressure, and prevalence of diabetes at baseline. Five hundred sixty-four par-
ticipants had only 1 eGFR follow-up measurement and were not included in the analysis
of sustained incidence.
1070corresponding proportions in patients with diabetes
were 8%, 23%, and 13% for sensitivity and 93%,
86%, and 94% for specificity (Table 5). In all par-
ticipants and in patients with diabetes, differences
between the UAE threshold and both CKD273
thresholds in the proportion of correctly versus
incorrectly classified individuals were significant
(P < 0.0001). With specificity set at 90%, thresholds
derived from the current dataset were 14 mg/min for
UAE and 0.163 for CKD273. The sensitivity of these
thresholds was lower for UAE than for CKD273
(15.6% vs. 20.8%; P ¼ 0.004). Assessed per
threshold, no marker improved IDI, but CKD273
(P < 0.0001), not UAE (P ¼ 0.086), enhanced NRI.Table 3. Predictive value of nested Cox regression models
Model (variables included)
First renal
endpoint
Sustained renal
endpoint
c2 P value c2 P value
Basic model (sex, age, MAP, DM)
þ Baseline eGFR 17.8 <0.0001 46.6 <0.0001
þ UAE 13.6 0.0002 2.79 0.094
þ CKD273 19.4 <0.0001 3.88 0.049
Basic model (sex, age, MAP, DM, eGFR)
þ UAE 15.4 <0.0001 4.90 0.027
þ CKD273 20.7 <0.0001 5.48 0.019
Basic model (sex, age, MAP, DM, eGFR, UAE)
þ CKD273 17.8 <0.0001 4.70 0.030
CKD273, urinary proteomic biomarker; DM, diabetes mellitus; eGFR, estimated glomer-
ular filtration rate derived from serum creatinine by the Chronic Kidney Disease
Epidemiology Collaboration formula; MAP, mean arterial pressure; UAE, urinary albumin
excretion rate.
c2 is the test statistic for the log likelihood ratio with 1 degree of freedom. All basic Cox
models were stratified by study center. P values are for the improvement of the fit
across nested models.
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Figure 2. Five-year absolute risk of a first (a,c) or sustained (b,d) renal endpoint in relation to urinary albumin excretion rate (UAE) at different
levels of CKD273 (a,b) and in relation to CKD273 at different levels of UAE (c,d). The analyses accounted for center, sex, age, mean arterial
pressure, presence of diabetes, and estimated glomerular filtration rate at baseline. In (a) and (b), risk functions span the 5th to 95th percentile
interval of UAE, and lines represent quartiles of the CKD273 distribution. In (c) and (d), risk functions span the 5th to 95th percentile interval of
CKD273 and lines represent quartiles of the UAE distribution. Midpoints of the quartiles (Q1, Q2, Q3, and, Q4) were 2.0, 3.5, 6.0, and 13.0 mg/min for
UAE and -0.81, -0.52, -0.25, and 0.16 for CKD273. P values are for the independent effect of UAE (PUAE) and CDK273 (PCKD). np and ne indicate the
number of participants at risk and the number of renal endpoints, respectively.
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In a sensitivity analysis, we applied a decline in eGFR
by 30% or more over 2 years as the renal endpoint.9
There were 33 cases among 2087 participants at risk.
After stratification by center and while accounting for
sex, age, mean arterial pressure, and prevalence of
diabetes, we constructed the 3-biomarker model as in
Table 2. In this model, the odds ratios were 2.03 (95%
CI, 1.36–3.03; P ¼ 0.0005) for UAE and 1.83 (95% CI,
1.22–2.74; P ¼ 0.0033) for CKD273. In all participants,
the UAE cutoff value of 20 mg/min and the CKD273Kidney International Reports (2017) 2, 1066–1075thresholds of 0.154 and 0.343 yielded sensitivities of
45%, 46%, and 42% and specificities of 95%, 88%,
and 94%, respectively.DISCUSSION
In keeping with research priorities endorsed by the
EMA8 and the Food and Drug Administration,13 we
investigated whether CKD273 can predict decline of
eGFR below 60 ml/min per 1.73 m2. The key findings of
the present study can be summarized as follows: (i) per1071
Table 4. Integrated discrimination improvement and net
reclassification improvement by adding CKD273 to the basic model
including covariables
Biomarkers
(threshold)
Integrated discrimination
improvement
Net reclassification
Improvement
IDI (%) CI (%) P value NRI (%) CI (%) P value
UAE continuous 0.69 –0.04 to 1.41 0.065 20.1 9.14 to 31.1 0.0003
UAE (20 mg/min) 0.50 –0.17 to 1.18 0.14 8.22 –1.16 to 17.6 0.086
CKD273
continuous
0.86 0.04 to 1.68 0.039 25.8 14.9 to 36.8 <0.0001
CKD273 (0.154) 0.34 –0.21 to 0.88 0.23 23.3 14.5 to 32.1 <0.0001
CKD273 (0.343) 0.57 –0.08 to 1.23 0.085 17.9 10.8 to 25.1 <0.0001
CI, confidence interval; CKD273, urinary proteomic biomarker; IDI, integrated discrimi-
nation improvement; NRI, net reclassification improvement; UAE, urinary albumin
excretion rate.
The basic reference models were stratified by study center and included sex, age,
mean arterial pressure, estimated glomerular filtration rate, and prevalence of diabetes
at baseline as covariables. The integrated discrimination improvement is the difference
between the discrimination slopes of basic models and basic models extended with
CKD273. The discrimination slope is the difference in predicted probabilities (%) be-
tween patients and control subjects. Control subjects are participants without incident
chronic kidney disease. The net reclassification improvement is the sum of the per-
centages of subjects reclassified correctly in the groups of cases and control subjects.
All estimates are provided with 95% confidence intervals.
CLINICAL RESEARCH C Pontillo et al.: CKD273 as Predictor of Early eGFR Decline1-SD increment in the urinary markers, eGFR decreased
0.82 ml/min per 1.73 m2 more with baseline CKD273
than with baseline UAE; (ii) the risk of a first and a
sustained renal endpoint increased with UAE and
CKD273; (iii) when published thresholds were
used,11,26,30 the sensitivity of both markers was low
with a specificity of approximately 80%, but the pro-
portion of correctly classified individuals was higher
for CKD273 than UAE; (iv) there was agreement be-
tween the CKD273 thresholds for early CKD published
before in patients with diabetes (0.154)11,30 and derived
from the current data (0.163); and (v) CKD273 contin-
uous, but not UAE continuous, increased IDI, while
both markers continuous and CKD273 also per
threshold improved NRI. The IDI and NRI indices
provide complementary information. Indeed, if addi-
tion of a biomarker to a model increases the predicted
probability in cases, this is reflected by a significant
increase in IDI, as was the case for CKD273 continuous
(Table 4). NRI indicates the extent to which a
biomarker improves diagnostic accuracy, which in theTable 5. Classification parameters by categories of urinary albumin excre
Biomarkers (threshold)
Correctly classified Incorrectly classified
Progressor Nonprogressor Progressor Nonprogressor Sensitivity
All participants
UAE (20 mg/min) 38 1607 352 90 30
CKD273 (0.154) 88 1522 302 175 33
CKD273 (0.343) 54 1621 336 76 42
Patients with diabetes
UAE (20 mg/min) 30 1097 328 78 28
CKD273 (0.154) 82 1014 276 161 34
CKD (0.343) 48 1103 310 72 40
CKD273, urinary proteomic biomarker; UAE, urinary albumin excretion rate.
1072current analyses amounted to 20.1% and 8.22% for
UAE continuous and per threshold and to 25.8%,
23.3%, and 17.9% for CKD273 continuous and per
0.154 and 0.343 threshold. Expert statisticians have
suggested that IDI and NRI have limitations.34 They
recommend retaining existing descriptive terms, such
as the true-positive and false-positive classification
rates (Table 5), and testing the null hypothesis of no
prediction increment from modeled regression co-
efficients (Table 2 and Figure 2). In our current ana-
lyses, we implemented these different approaches.34
Whatever method was used, CKD273 provided a
meaningful improvement in risk stratification.
While adjusting for covariables and baseline eGFR,
our study suggests that CKD273, independent from
UAE, predicts decline in glomerular filtration and
progression to stage 3 CKD. The clinical relevance of
our observations pertains to the clinical management
of patients and the design of intervention trials for
patients at risk for CKD. In the present study, we
intentionally recruited participants with an eGFR of
60 ml/min per 1.73 m2 or higher and implemented
eGFR <60 ml/min per 1.73 m2 as the primary
endpoint. At this relatively early phase, interventions
aimed at reversing or stopping the disease process
before irreversible renal anatomic disruption occurs
remain a potentially achievable therapeutic target.35
Timely intervention would substantially increase the
quality of life of patients while reducing health care
costs. For instance, type 2 diabetes currently accounts
for 15% of the health care budget in Europe.36 Pre-
venting or delaying the complications of diabetic
nephropathy might reduce health care costs 6 fold.36
From the viewpoint of clinical trial design,
measuring CKD273 will help in selecting patients at
risk for progressive CKD for enrollment in interven-
tion studies, thereby reducing the number of patients
to be randomized and curtailing the follow-up dura-
tion required to achieve an intermediate endpoint
(e.g., CKD stage 3 as recommended by the EMA).8
This approach is presently being implemented in thetion rate and CKD273 at baseline
Classification parameters
(%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
82 10 95
83 23 90
83 14 96
77 8 93
79 23 86
78 13 94
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ORITY trial (proteomic prediction and renin angio-
tensin aldosterone system inhibition prevention of
early diabetic nephropathy in type 2 diabetic patients
with normal albumin excretion).30
Renal interstitial fibrosis is a universal predictor of
the decline in renal function37 and is characterized by
exaggerated deposition of extracellular matrix by an
expanding population of fibroblasts and myofibro-
blasts.38 Consistent with the pathophysiology of
CKD,37,38 the majority of peptide fragments included in
CKD273 are dysregulated collagen fragments. Exami-
nation of the top 20 sequenced peptide fragments with
a differential signal amplitude between progressors and
nonprogressors revealed that 15 were fragments of
collagen I or III, which were all downregulated in cases
(Table S1). Higher levels of tissue inhibitor of matrix
metalloproteinase type 1, as observed in patients with
renal dysfunction,39 might inhibit the breakdown of
collagen. This process might be further enhanced by
increased crosslinking of collagen, inhibiting physio-
logic degradation of collagen by matrix metal-
loproteases.40 In addition, 4 fibrinogen fragments were
upregulated. Fibrinogen plays a role in the pathogen-
esis of fibrotic disorders by acting as a profibrotic
ligand for a variety of cellular surface receptors. In a
mouse model of renal interstitial fibrosis induced by
obstruction of the ureter,41,42 pharmacologic or genetic
depletion of fibrinogen protected the kidneys from
fibrosis. In selected patients with hypertensive ne-
phropathy, the urinary excretion of the fibrinogen a
chain was 15-fold higher compared with that of healthy
control subjects and was associated with a rapid
decline in renal function (6.7 ml/min per 1.73 m2 per
year).43 Of particular interest among the sequenced
peptides (Table S1) is a fragment of the mucin-1 sub-
unit a, an extracellular protein that is shed from renal
tubular epithelium and, which as previously reported
in this journal,44 is a strong predictor of renal
dysfunction.
The present study must also be interpreted within
the context of its limitations. First, in line with the
EMA’s recommendations,8 we chose as primary renal
endpoint a decrease in eGFR from baseline to follow-up
by at least 10 ml/min per 1.73 m2 to less than 60 ml/min
per 1.73 m2. This endpoint has not yet been firmly
validated in terms of adverse health outcomes. How-
ever, a sensitivity analysis based on a decrease in eGFR
by 30% or more over 2 years9 confirmed the predictive
value of CKD273. This relatively small decline in eGFR
is a strong predictor of progression to end-stage renal
disease and death.9 Second, selection of individuals
with an eGFR of 60 ml/min per 1.73 m2 or higher
resulted in a prevalence of albuminuria ($20 mg/min)26Kidney International Reports (2017) 2, 1066–1075of only 6.2%. Therefore our current results cannot be
extrapolated to patients with albuminuria or protein-
uria. Third, the participants available for analysis from
the Human Urine Proteome Database17 were enrolled in
studies with different designs, including 2 randomized
clinical trials,19,20 1 population study,23 and 3 smaller
subgroups of patients with diabetes recruited in
Western Europe16,21 and Australia.22 Although het-
erogeneity might be considered a limitation, it might
also facilitate generalizability. Fourth, for 564 partici-
pants, only a single follow-up measurement of eGFR
was available. However, results involving first and
sustained renal endpoints were consistent (Tables 2
and 3). Finally, to compute albuminuria, we had to
assume a urinary volume of 1500 ml/day in 165 par-
ticipants (7.9%). However, excluding these partici-
pants did not materially alter our results.
In conclusion, CKD273 adds to the prediction of
stage 3 CKD, at which intervention remains an
achievable therapeutic target. Our study confirms a
CKD273 threshold of 0.154 for clinical application.
Nevertheless, future translation of our current results
into widespread day-to-day practice will be chal-
lenging.13,45 Urinary proteomic analysis is complex,
requires expertise only available in few centers,46,47
and for now remains costly compared with other
diagnostic tests employed in the management of
patients who have or are at risk for having CKD.
However, a recent health-economic assessment48 indi-
cated that the application of CKD273 in type 2 diabetic
patients is cost effective. Future trials involving
CKD273 should demonstrate the exact magnitude of the
cost–benefit ratio supporting implementation of
CKD273 in clinical practice. In addition, CKD273 is a
biomarker reflecting the pathophysiology of CKD and
is thereby generating insights into potentially effective
pharmacologic approaches to manage this high-risk
condition affecting millions of people worldwide.2–4DISCLOSURE
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